Akari Therapeutics (NASDAQ:AKTX) Stock Price Crosses Below Two Hundred Day Moving Average – Should You Sell?

Akari Therapeutics PLC (NASDAQ:AKTX) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.65 and traded as low as $0.2220. Akari Therapeutics shares last traded at $0.2250, with a volume of 272,148 shares.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on AKTX. LADENBURG THALM/SH SH started coverage on shares of Akari Therapeutics in a report on Monday, January 5th. They issued a “buy” rating and a $1.00 price objective for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Akari Therapeutics in a research note on Wednesday, January 21st. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $2.53.

Akari Therapeutics Price Performance

The stock’s 50 day moving average price is $0.29 and its two-hundred day moving average price is $0.65.

Hedge Funds Weigh In On Akari Therapeutics

An institutional investor recently raised its position in Akari Therapeutics stock. Cresset Asset Management LLC boosted its position in shares of Akari Therapeutics PLC (NASDAQ:AKTX) by 4,368.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 822,468 shares of the biopharmaceutical company’s stock after buying an additional 804,060 shares during the quarter. Cresset Asset Management LLC owned approximately 2.52% of Akari Therapeutics worth $831,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 5.06% of the company’s stock.

Akari Therapeutics Company Profile

Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.

Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease.